Anthem Biosciences came to market through an IPO that opened on 14 July 2025 and closed on 16 July 2025, and the shares listed on 21 July 2025 on BSE, NSE. The price band was ₹540 to ₹570 per share and one lot was 26 shares, so the minimum application was ₹14,820. The issue size was ₹3395 crore. The whole issue was an offer for sale, so the proceeds went to the selling shareholders rather than the company.
Kfin Technologies Limited was the registrar to the issue, and Jm Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd were the lead managers.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Founded in 2006, Anthem Biosciences Limited is a technology and innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO) with vertically integrated operations covering drug discovery, development, and manufacturing activities.
The company caters to varied customers such as innovative, early-stage biotech companies and big pharma companies globally.The company produces niche fermentation-based APIs, such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the half-year ended September 30, 2024, the company was involved in the production of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been funded since discovery. The company had 196 projects as of September 30 2024:
170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of March 31, 2024, and September 30, 2024, the company had more than 425 and 550 customers for our CRDMO and specialty ingredients business, distributed across more than 44 countries, including Europe, Japan, and the U.S.As of March 31, 2024, the company had more than 150 customers, ranging from small biotech to big pharma.As of 30 September 2024, the company has one patent in India, seven foreign, and 24 pending foreign patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of 30 September 2024, the company has 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, specialists in different in-vivo non-clinical research and chemical engineers.
As described in the offer document.
| Metric | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Anthem Biosciences IPO: Institutional buyers select Rs 1,016 crore worth of shares through anchor book. World marquee investors such as Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, Optimix Wholesale Global Emerging Markets Share Trust, PineBridge Global Funds, and Societe Generale acquired the pharma firm's shares through anchor book.
Most asset management firms such as HDFC Mutual Fund, ICICI Prudential AMC, Kotak Mahindra Trustee, Nippon Life India Trustee, Aditya Birla Sun Life AMC, Axis Mutual Fund, Whiteoak Capital Mutual Fund, Franklin, Mirae Asset, UTI MF, Motilal Oswal MF, Quant Mutual Fund, Edelweiss Trusteeship, and Bandhan Mutual Fund also invested the lion's share of money (approximately Rs 604.4 crore) in to Anthem Biosciences through anchor book.
Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, Ishaan Bhardwaj. Promoter holding 77.23% before the issue and 74.68% after.
Work out the listing gain for this IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Anthem Biosciences IPO was a ₹3,395 crore book-built issue, made up entirely of an offer for sale. It was priced at ₹540–₹570 per share with a lot size of 26 shares (₹14,820). The IPO was open from July 14 to July 16, 2025. Shares listed on BSE and NSE on July 21, 2025 at ₹723.05, a 26.9% premium to the issue price of ₹570. Kfin Technologies Limited is the registrar.
Jm Financial Limited and 3 other book running lead managers manage the issue.
The price band of Anthem Biosciences IPO is ₹540 to ₹570 per share.
The lot size of Anthem Biosciences IPO is 26 shares.
The minimum investment for Anthem Biosciences IPO is approximately ₹14,820 based on the upper price band.
The allotment date of Anthem Biosciences IPO is Jul 17, 2025.
No GMP quote could be verified as recorded before Anthem Biosciences IPO listed. A grey-market observation of ₹170 per share was recorded on 21 Jul 2025, 6:30 AM IST, but without a verified listing timestamp it is not treated as the final pre-listing GMP. The shares listed at ₹723.05. GMP is unofficial and does not forecast or guarantee the actual listing price.
Anthem Biosciences IPO listed on Jul 21, 2025. It was issued at ₹723.05(NSE) and is currently around ₹858.85 as on 3-Nov-2026 3:30 PM, which is approximately 50.7% versus issue price. The 52-week high is ₹977.55.
You can check Anthem Biosciences IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Anthem Biosciences IPO allotment status on Rupix for quick and easy access.
₹540 to ₹570 per share, against a face value of ₹2. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 26 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹14,820.
₹14,820, for one lot of 26 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 14 July 2025 and closed on 16 July 2025.
The basis of allotment was published on 17 July 2025 by Kfin Technologies Limited, and allotted shares were credited to demat accounts before listing.
The shares listed on 21 July 2025 on BSE, NSE.
The issue size was ₹3395 crore. The offer for sale was 5,95,61,404 shares (aggregating up to ₹3395 crore).